The Leukemia & Lymphoma Society at ASCO 2025: Blood cancers and future oncological trends

ASCO 2025 spotlighted new data across haematologic cancers this year.

To discuss announcements in liquid cancers further, as opposed to solid tumours, pharmaphorum spoke with Dr Lore Gruenbaum, chief scientific officer at the Leukemia & Lymphoma Society (LLS).

Dr Gruenbaum describes the landscape of unmet need in leukaemia and lymphoma, as well as noteworthy abstracts on blood cancers presented at the Congress, in addition to explaining LLS’ own Therapy Acceleration Program (TAP) and future oncological trends discussed at the conference.

Watch this and other conversations from ASCO 2025 here.